S-1: BioCardia Announces Proposed Public Offering of Common Stock and Warrants

BioCardia, Inc. files for a best efforts public offering of common stock, pre-funded warrants, and common warrants to raise capital for general corporate purposes.

Summary

• BioCardia, Inc. has filed a registration statement for a proposed public offering.
• The offering includes shares of common stock, pre-funded warrants to purchase common stock, and common warrants to purchase common stock.
• Each share of common stock or pre-funded warrant is being sold together with one-half of a common warrant.
• The common warrants will be exercisable immediately and expire five years from the date of issuance, with an exercise price equal to a percentage of the combined public offering price.
• Pre-funded warrants are offered to purchasers whose ownership would exceed 4.99% (or 9.99%) of the outstanding common stock after the offering.
• The company intends to use the net proceeds from the offering for working capital and general corporate purposes, including advancing biotherapeutic candidates and the biotherapeutic delivery partnering business.
• Certain members of the Board of Directors and a non-director executive officer have indicated preliminary interest in purchasing up to shares of common stock and accompanying common warrants, resulting in expected gross proceeds of approximately $ million.
• The offering is being conducted on a best efforts basis through A.G.P./Alliance Global Partners.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol BCDA.
• The last reported closing sale price of the common stock on Nasdaq was $ per share on , 2024.
• There is no established trading market for the common warrants, and the company does not expect one to develop.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company is raising capital, it is doing so through a best efforts offering, and there are risks associated with the company's business and the offering itself. The company is currently not in compliance with Nasdaq listing requirements, specifically the requirement to maintain a minimum market value of listed securities of at least $35.0 million.

Positives

• The offering aims to provide BioCardia with additional capital for working capital and general corporate purposes.
• The potential participation of board members and an executive officer could signal confidence in the company's prospects.
• The immediate exercisability of the warrants provides investors with potential immediate returns.

Negatives

• The offering is on a 'best efforts' basis, meaning there is no guarantee that the company will raise the desired amount of capital.
• The absence of a minimum offering amount means the company could proceed with limited funds, potentially impacting its ability to execute its business plan.
• The lack of an established trading market for the warrants limits their liquidity.
• The offering may cause dilution to existing shareholders.
• The company is currently not in compliance with Nasdaq listing requirements, specifically the requirement to maintain a minimum market value of listed securities of at least $35.0 million.

Risks

• The company's success depends on obtaining approval for and commercializing the CardiAMP Cell Therapy System, which is uncertain.
• The company's cell therapy systems are based on novel technology, making it difficult to predict development costs and regulatory approval timelines.
• The company may encounter delays in clinical studies and difficulties enrolling patients.
• The company relies on third parties for manufacturing, diagnostic protocol development, research, and preclinical and clinical testing.
• The company faces substantial competition, which may result in others discovering, developing or commercializing products before, or more successfully, than the company does.
• The company has limited experience manufacturing therapeutic candidates in commercial quantities.
• The company may fail to obtain and sustain an adequate level of reimbursement for its products by third-party payors.
• The company may fail to attract and keep senior management and key scientific personnel.
• The company may be exposed to additional risks as a result of its reverse merger transaction.
• The company's annual and quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts.
• The company may be at risk of securities class action litigation.
• The company is currently not in compliance with Nasdaq listing requirements, specifically the requirement to maintain a minimum market value of listed securities of at least $35.0 million.

Future Outlook

The company intends to use the net proceeds from this offering for general corporate purposes, which may include working capital and other general corporate purposes, which include, but are not limited to, advancing our investigational biotherapeutic candidates and our biotherapeutic delivery partnering business.

Industry Context

The company operates in the clinical-stage biopharmaceutical industry, which is characterized by high risk, long development timelines, and significant capital requirements. The success of the company's product candidates is dependent on positive clinical trial results, regulatory approvals, and market acceptance.

Comparison to Industry Standards

• It is difficult to compare BioCardia's results to industry standards due to the unique nature of its cell therapy systems and the lack of approved cell-based therapies for cardiac indications in the United States.
• Comparable companies in the regenerative medicine space include Vericel Corporation and Organogenesis Holdings Inc., but their specific technologies and target markets differ from BioCardia's.
• The success of BioCardia's CardiAMP Cell Therapy System will depend on its ability to demonstrate superior efficacy and safety compared to existing treatments for heart failure and angina.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• Employees may be affected by the company's ability to execute its business plan with the proceeds from the offering.
• Customers and partners may be impacted by the company's ability to advance its biotherapeutic candidates and the biotherapeutic delivery partnering business.
• Creditors may be affected by the company's financial condition and its ability to repay its debts.

Next Steps

• The company will offer and sell the securities through the Placement Agent on a reasonable best efforts basis.
• The company will deliver the securities to the investors upon receipt of funds.
• The company will use the net proceeds from the offering for general corporate purposes, including advancing biotherapeutic candidates and the biotherapeutic delivery partnering business.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, BioCardia, BCDA, capital raise, clinical-stage, cell therapy, CardiAMP, CardiALLO, Helix, AGP, Alliance Global Partners